Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
106.6 USD | -0.66% | -0.92% | -3.15% |
Apr. 29 | Abbott's Dissolving Stent Gets FDA Approval For Arteries Below the Knee | MT |
Apr. 26 | Dexcom's profit beats estimates on strong glucose monitor demand | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-3.15% | 186B | |
-2.46% | 107B | |
-4.28% | 67.44B | |
+2.70% | 50.03B | |
+16.45% | 47.81B | |
+4.79% | 41.03B | |
+2.76% | 26.85B | |
+4.15% | 25.82B | |
-0.74% | 25.01B | |
+16.55% | 24.74B |
- Stock Market
- Equities
- ABT Stock
- News Abbott Laboratories
- Abbott Laboratories' Q1 Adjusted Earnings Down, Revenue Up; 2024 Outlook Narrowed